The renewed strength in TAVR, following a slowdown last year tied to heart team capacity challenges at hospitals, prompted ...

Edwards Lifesciences Corporation EW reported second-quarter 2025 adjusted earnings per share (EPS) of 67 cents, which ...

Edwards Lifesciences has lifted its 2025 profit outlook to between 9%-10%, up from 8%-10%, amid strong Q2 2025 performance in its Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral ...

Background Current risk scores inadequately predict long-term mortality after transcatheter aortic valve replacement (TAVR), ...

Edwards Lifesciences stock surged late Thursday after the medtech hiked its outlook following a key setback for rival Boston ...

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2025. Recent Highlights. Q2 sales g ...

Edwards Lifesciences EW is gaining from the robust uptake of its premium surgical technologies. The company’s Transcatheter ...

The study isn’t intended to sway clinical decision-making, but to make doctors aware of the impact of their choices.

JenaValve announced today that it began patient enrollment in the ARTIST study evaluating its Trilogy TAVR system.

Objectives: We have continuously performed conventional aortic valve replacement (AVR) with median sternotomy as the primary approach because we believe that it is the safest approach, and even very ...

RATES of permanent pacemaker implantation (PPI) exceed 20% in patients with aortic regurgitation (AR). A new retrospective multicentre study focused on evaluating the incidence and risk factors for ...

BACKGROUND: Thoracic (TAA) and abdominal (AAA) aortic aneurysm are life-threatening diseases characterized by dilation, inflammation, and structural weakness; development of pharmacological therapies ...